NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $597,706 | -60.1% | 558,604 | -3.5% | 0.00% | -55.6% |
| Q2 2023 | $1,499,315 | -50.6% | 578,886 | -22.1% | 0.01% | -52.6% |
| Q1 2023 | $3,032,415 | -10.3% | 743,239 | +10.4% | 0.02% | -17.4% |
| Q4 2022 | $3,379,284 | +276.3% | 673,164 | +880.6% | 0.02% | +228.6% |
| Q3 2022 | $898,000 | -83.3% | 68,649 | -80.5% | 0.01% | -80.6% |
| Q1 2022 | $5,367,000 | -29.3% | 351,943 | -17.9% | 0.04% | -29.4% |
| Q4 2021 | $7,587,000 | -21.2% | 428,426 | -6.4% | 0.05% | -21.5% |
| Q3 2021 | $9,626,000 | +93.1% | 457,946 | +81.1% | 0.06% | +91.2% |
| Q2 2021 | $4,986,000 | -25.6% | 252,823 | +9.7% | 0.03% | -34.6% |
| Q1 2021 | $6,700,000 | +1.3% | 230,472 | +5.6% | 0.05% | -10.3% |
| Q4 2020 | $6,611,000 | +81.6% | 218,206 | -4.6% | 0.06% | +52.6% |
| Q3 2020 | $3,641,000 | -7.5% | 228,830 | +14.8% | 0.04% | -11.6% |
| Q2 2020 | $3,936,000 | +131.4% | 199,396 | +44.5% | 0.04% | +95.5% |
| Q1 2020 | $1,701,000 | – | 137,964 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
| Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
| Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
| Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
| StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
| Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
| First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
| GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
| Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
| Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |